Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLV939)

Drug Name

AR1001 Drug Info

Synonyms

N-METHYLBENZYLAMINE; 103-67-3; N-Benzylmethylamine; N-methyl-1-phenylmethanamine; Methylbenzylamine; Benzylmethylamine; Benzyl(methyl)amine; Benzenemethanamine, N-methyl-; N-Benzyl-N-methylamine; Benzylamine, N-methyl-; N-Methy-N-benzylamine; Benzyl-methyl-amine; N-methyl-N-benzylamine; methyl benzylamine; N-Methyl(phenyl)methanamine; BENZYLAMINE, N-METHYL; N-benzyl-methylamine; N-methyl benzylamine; N-methyl-N-(phenylmethyl)amine; Benzylmethyl-d3-amine; NSC 8059; N-methylbenzenemethanamine; MFCD00008289; N-methyl-1-phenyl-methanamine; 7KN7F4X49E; NSC-8059; methylbezylamine; benzyl methylamine; benzyl-methylamine; HNMeBzl; N-benzylmethanamine; benzyl methyl amine; methyl-benzyl amine; EINECS 203-133-4; N-benzyl methylamine; N-methyl-benzylamine; N-methylbenzyl amine; N-benzyl methyl amine; N-benzyl-methyl amine; N-methyl -benzylamine; N-methyl benzyl amine; N-methyl-benzyl amine; (-)-methylbenzylamine; Methylbenzylamine, N-; omega-Methylaminotoluene; Spectrum_001362; AI3-26793; Methyl(phenylmethyl)amine; N-benzyl-N-methyl-amine; N-methyl-N-benzyl amine; Spectrum4_001764; Spectrum5_000347; Racemic methylbenzyl amine; N-methyl-benzenemethanamine; EC 203-133-4; N-(Phenylmethyl)methylamine; N-Benzylmethylamine, 97%; SCHEMBL2271; CHEMBL1338; UNII-7KN7F4X49E; KBioGR_002247; KBioSS_001842; MLS004773900; DTXSID9048439; KBio2_001842; KBio2_004410; KBio2_006978; NSC8059; (+)-2-Methylbutylp-aminocinnamate; STR02536; AR1001; AKOS000119094; CS-W007426; HY-W007426; SDCCGMLS-0066901.P001; NCGC00166047-01; SMR000112361; FT-0631560; M0164; EN300-18191; W-108843; BRD-K44558320-003-01-7; Q23978278; Z57327124; F2190-0316; InChI=1/C8H11N/c1-9-7-8-5-3-2-4-6-8/h2-6,9H,7H2,1H

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 3	[1]

Cross-matching ID

PubChem CID: 7669
TTD Drug ID: DMLV939

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phosphodiesterase 5 (PDE5)	TTUZ196	NOUNIPROTAC	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05531526) A Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 Over 52 Weeks in Participants With Early Alzheimer's Disease (Polaris-AD). U.S.National Institutes of Health.
2	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight